Internal Medicine, Hematology & Oncology · La Mesa, CA
NPI
1164583639
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
5555 Grossmont Center Dr
La Mesa, CA, 91942
Phone (619) 644-3030
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.5M
320,547 services
Medicare patients, 2024
579
Average age 73
Drug cost, 2024
$6.8M
1,499 prescriptions
Company payments, 2025
$2,344
From 35 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kai Zu was code J1439 (injection, ferric carboxymaltose, 1 mg), 66,000 times for 41 patients. In total Kai Zu billed 320,547 services in 107 codes, and Medicare paid $5.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-08-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 66,000 | 41 | $0.87 | $57K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 64,580 | 34 | $2.31 | $149K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 18,400 | 15 | $44.25 | $814K |
| J0897 Injection, denosumab, 1 mg | Office | 4,380 | 16 | $20.31 | $89K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,625 | 42 | $0.09 | $232 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,780 | 35 | $0.65 | $1,156 |
| 99213 Office E&M - Established | Office | 807 | 353 | $75.02 | $61K |
| 96375 Injection Administration | Office | 585 | 55 | $14.43 | $8,440 |
| 96372 Injection Administration | Office | 456 | 70 | $12.99 | $5,922 |
| 96413 Chemotherapy Administration | Office | 453 | 67 | $124.49 | $56K |
| 99214 Office E&M - Established | Office | 356 | 237 | $104.82 | $37K |
| J9045 Injection, carboplatin, 50 mg | Office | 328 | 12 | $2.77 | $909 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 249 | 127 | $14.31 | $3,562 |
| 96365 Intravenous Infusion, Hydration | Office | 195 | 52 | $60.53 | $12K |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 162 | 29 | $0.64 | $103 |
By year: 2022 $4.5M for 287,080 services; 2023 $4.4M for 328,011 services; 2024 $5.5M for 320,547 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kai Zu prescribed most often to Medicare patients was Anastrozole, with 125 prescriptions and refills. In total Kai Zu wrote 1,499 Medicare prescriptions that cost $6.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 125 | 214 | 23 | $1,450 |
| Ondansetron Hcl Generic | 90 | 90 | 47 | $1,364 |
| Omeprazole Generic | 69 | 105 | 25 | $376 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 65 | 65 | 17 | $2,070 |
| Morphine Sulfate Er Morphine Sulfate | 60 | 60 | Under 11 | $3,183 |
| Brukinsa Zanubrutinib | 49 | 49 | Under 11 | $597K |
| Prednisone Generic | 48 | 52 | 16 | $324 |
| Potassium Chloride Generic | 47 | 61 | 17 | $256 |
| Levothyroxine Sodium Generic | 38 | 72 | Under 11 | $279 |
| Lenalidomide Generic | 37 | 37 | Under 11 | $543K |
| Reblozyl Luspatercept-Aamt | 34 | 34 | Under 11 | $480K |
| Dexamethasone Generic | 34 | 34 | 14 | $531 |
| Hydroxyurea Generic | 31 | 41 | Under 11 | $1,056 |
| Calquence Acalabrutinib Maleate | 29 | 29 | Under 11 | $444K |
| Ibrance Palbociclib | 27 | 27 | Under 11 | $414K |
Brand drugs: - claims; generic drugs: 1,001 claims; opioid claims: 241.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kai Zu $2,344 ($2,344 in general payments such as food, travel and fees) from 35 companies. The largest payer was Daiichi Sankyo Inc. with $650.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 1 | $650 |
| Celgene Corporation BMY | 10 | $221 |
| Pfizer Inc. PFE | 8 | $150 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $102 |
| BeOne Medicines USA, Inc. ONC | 3 | $99.52 |
| Merck Sharp & Dohme LLC MRK | 3 | $86.72 |
| Genzyme Corporation SNY | 3 | $80.91 |
| GlaxoSmithKline, LLC. GSK | 3 | $76.24 |
| Karyopharm Therapeutics Inc. KPTI | 2 | $69.56 |
| PharmaEssentia USA Corporation 6446.TW | 2 | $69.17 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.